GeneOne Life Science, Inc.
- Country
- π°π·South Korea
- Ownership
- Public
- Established
- 1976-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.genels.com
Clinical Trials
13
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (13 trials with phase data)β’ Click on a phase to view related trials
GLS-5310 Vaccine in Healthy Volunteers as a Booster for SARS-CoV-2 (COVID-19)
- Conditions
- HealthyCOVID-19
- Interventions
- Drug: GLS-5310 (Group 3)Drug: GLS-5310 (Group 2)Drug: GLS-5310 (Group 4)Drug: GLS-5310 (Group 1)
- First Posted Date
- 2022-01-10
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- GeneOne Life Science, Inc.
- Target Recruit Count
- 69
- Registration Number
- NCT05182567
- Locations
- πΊπΈ
Meridian Clinical Research, Lincoln, Nebraska, United States
π΅π·Clinical Research Puerto Rico, San Juan, Puerto Rico
GLS-5310 Vaccine in Healthy Volunteers for the Prevention of SARS-CoV-2 (COVID-19)
- Conditions
- HealthyCovid19
- First Posted Date
- 2021-10-20
- Last Posted Date
- 2021-10-20
- Lead Sponsor
- GeneOne Life Science, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05085639
- Locations
- π΅π·
Clinical Research Puerto Rico, San Juan, Puerto Rico
π΅π·University of Puerto Rico, San Juan, Puerto Rico
GLS-5310 Vaccine for the Prevention of SARS-CoV-2 (COVID-19)
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- GeneOne Life Science, Inc.
- Target Recruit Count
- 183
- Registration Number
- NCT04673149
- Locations
- π°π·
Korea University Guro Hospital, Seoul, Korea, Republic of
GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19)
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- GeneOne Life Science, Inc.
- Target Recruit Count
- 132
- Registration Number
- NCT04590547
- Locations
- πΊπΈ
Baton Rouge General Medical Center, Baton Rouge, Louisiana, United States
π§π¬MHAT Kozlodui, Kozloduy, Bulgaria
π§π¬SHATPPD d-r Dimitar Gramatikov, Department of Pneumology, Ruse, Bulgaria
GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19)
- First Posted Date
- 2020-05-29
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- GeneOne Life Science, Inc.
- Target Recruit Count
- 184
- Registration Number
- NCT04408183
- Locations
- πΊπΈ
Sinus and Nasal Specialists of Louisiana, Baton Rouge, Louisiana, United States
πΊπΈUniversity of Pennsylvania, Philadelphia, Pennsylvania, United States
πΊπΈConroe Willis Medical Reasearch, Conroe, Texas, United States
- Prev
- 1
- 2
- 3
- Next